Sales 2024 * | 681M 54.44B | Sales 2025 * | 836M 66.78B | Capitalization | 3.26B 260B |
---|---|---|---|---|---|
Net income 2024 * | -109M -8.71B | Net income 2025 * | -5M -399M | EV / Sales 2024 * | 4.49 x |
Net cash position 2024 * | 199M 15.86B | Net cash position 2025 * | 306M 24.42B | EV / Sales 2025 * | 3.53 x |
P/E ratio 2024 * |
-28.2
x | P/E ratio 2025 * |
592
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.37% |
Latest transcript on HUTCHISON CHINA MED.
Managers | Title | Age | Since |
---|---|---|---|
Wei Guo Su
CEO | Chief Executive Officer | 66 | 31/12/04 |
Chig Fung Cheng
DFI | Director of Finance/CFO | 57 | 30/06/08 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/12/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chi Keung To
CHM | Chairman | 72 | 31/12/99 |
Graeme Jack
BRD | Director/Board Member | 73 | 28/02/17 |
Dan Eldar
BRD | Director/Board Member | 70 | 31/07/16 |
1st Jan change | Capi. | |
---|---|---|
+26.47% | 664B | |
+27.89% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.94% | 234B | |
+4.89% | 199B | |
-10.22% | 196B | |
-4.04% | 148B |